"

Whilst the U.S. National Genome Project started in 1990, with grim prospects of completion by the target finish date of year 2005, Cerela Genomics, a private company, declared to finalize the project by the year 2000 and accomplished this. After this revolutionary event, genome analysis is no longer purely a science matter for scientists but a huge business matter to the corporate world, as it opens the door to a Life Science Revolution, an impact that is estimated to surpass that of the IT revolution. This conference is aimed to paint the rapidly changing landscape of the life science industry in 2002. It will look into the impact of current and future cross-industry mergers and define the strategic meaning and advantages behind it. It will also study how the innovations in genomics and proteomics will impact R&D in pharmaceutical, chemical and agricultural companies. Furthermore, there will be discussions by prominent speakers on the incubation of genome venture companies and the problems to be solved for the development of this industry. This conference is a must for senior executives mapping the road ahead for the 'Life Science Revolution'.